The influence of hyperlipoproteinemia on in vitro distribution of amiodarone and desethylamiodarone in human and rat plasma

Pharmaceutical Research

Volumn 24, Issue 4, 2007, Pages 672-678

  Shayeganpour, Anooshirvan ^a   Lee, Stephen D ^b   Wasan, Kishor M ^b   Brocks, Dion R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Amiodarone; Desethylamiodarone; Distribution; Hyperlipidemia; Pharmacokinetics

Indexed keywords

AMIODARONE; DEETHYLAMIODARONE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; NONHUMAN; PRIORITY JOURNAL; RAT; ULTRACENTRIFUGATION;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CHOLESTEROL; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEINS; LIPOPROTEINS, LDL; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TRIGLYCERIDES;

EID: 33947162563     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9186-z     Document Type: Article

References (20)

1. N. A. Estes( 3rd, J. Weinstock, P. J. Wang, M. K. Homoud, and M. S. Link. Use of antiarrhythmics and implantable cardioverter-defibrillators in congestive heart failure. Am. J. Cardiol. 91:45D-52D (2003).
2. J. A. Reiffel and G. V. Naccarelli. Antiarrhythmic drug therapy for atrial fibrillation: are the guidelines guiding clinical practice? Clin. Cardiol.29:97-102 (2006).
3. A. Shayeganpour, A. S. Jun, and D. R. Brocks. Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm. Drug Dispos. 26:249-257 (2005).
4. P. A. Wyss, M. J. Moor, and M. H. Bickel. Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. J. Pharmacol. Exp. Ther. 254:502-507 (1990).
5. R. Latini, A. Bizzi, M. Cini, E. Veneroni, S. Marchi, and E. Riva. Amiodarone and desethylamiodarone tissue uptake in rats chronically treated with amiodarone is non-linear with the dose. J. Pharm. Pharmacol. 39:426-431 (1987).
6. J. W. Mason. Amiodarone. N. Engl. J. Med. 316:455-466 (1987).
7. M. R. Lalloz, P. G. Byfield, R. M. Greenwood, and R. L. Himsworth. Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. J. Pharm. Pharmacol. 36:366-372 (1984).
8. D. R. Brocks and K. M. Wasan. The influence of lipids on stereoselective pharmacokinetics of halofantrine: important implications in food-effect studies involving drugs that bind to lipoproteins. J. Pharm. Sci. 91:1817-1826 (2002).
9. A. Shayeganpour, A. O. El-Kadi, and D. R. Brocks. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms. Drug Metab. Dispos. 34:43-50 (2006).
10. I. Kodama, K. Kamiya, and J. Toyama. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol. 84:20R-28R (1999).
11. J. Kharidia and N. D. Eddington. Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. Biopharm. Drug Dispos. 17:93-106 (1996).
12. K. M. Wasan, M. Ramaswamy, M. P. McIntosh, C. J. Porter, and W. N. Charman. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas. J. Pharm. Sci. 88:185Y190 (1999).
13. K. M. Wasan and J. S. Conklin. Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol. Clin. Infect. Dis. 24:78-80 (1997).
14. K. M. Wasan, A. L. Kennedy, S. M. Cassidy, M. Ramaswamy, L. Holtorf, J. W. Chou, and P. H. Pritchard. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42:3146-3152 (1998).
15. A. Shayeganpour, V. Somayagi, and D. R. Brocks. A liquid chromatography-mass spectrometry assay method for simultaneous determination of amiodarone and desethylamiodarone in rat specimens. Biomed. Chromatogr. In Press.
16. J. Koch-Weser and E. M. Sellers. Binding of drugs to serum albumin (first of two parts). N. Engl. J. Med. 294:311-316 (1976).
17. R. M. Procyshyn, T. Ho, and K. M. Wasan. Competitive displacement of clozapine from plasma proteins in normolipidemic and hyperlipidemic plasma samples: clinical implications. Drug Dev. Ind. Pharm. 31:331-337 (2005).
18. K. M. Wasan and S. M. Cassidy. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87:411-424 (1998).
19. J. L. Bauman, H. Takahashi, and J. H. Fischer. Clinical Pharmacokinetics of Oral Antiarrhythmic Drugs., Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring, Lippincott Williams & Wilkins, Philadelphia, 2006.
20. P. T. Pollak and M. H. Tan. Elevation of high-density lipoprotein cholesterol in humans during long-term therapy with amiodarone. Am. J. Cardiol. 83:296-300, A7 (1999).